All In Biotech

Drug Trial Radar · NCT06427668

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

A Phase 2, Randomized, Placebo-controlled, Double-Blind Multicenter Study to Assess the Safety, Tolerability, and Pharmacodynamics (PD) in Adult Participants With Mild-to Moderate Alzheimer's Disease (AD) Administered SPG302

Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Actual

Start

Jul 29, 2024

Primary completion

Dec 2025

Study completion Jun 2026

Sponsor

Lead sponsor
SpinogenixIndustry
Sponsor type
Industry
First posted
May 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.

Conditions

  • Alzheimer Disease

Interventions

  • SPG302Drug

    synthetic small molecule

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Electroencephalogram (EEG) at resting state and at auditory evoked P300 from baseline to endpointTime frame: 8 months
  2. Change in Alzheimer's Disease Assessment Scale-Cog (ADAS-COG) total score from baseline to endpointTime frame: 8 months
  3. Change in Mini-Mental State Examination (MMSE) from baseline to endpointTime frame: 8 months
  4. C-SSRS (Columbia Suicide Severity Rating Scale)Time frame: 8 months
  5. Change in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS - CGIC) from baseline to endpointTime frame: 8 months
  6. Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale from baseline to endpointTime frame: 8 months
  7. Quality of Life in Alzheimer's Disease (QOL-AD) from baseline to endpointTime frame: 8 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • St Vincent's Hospital

    Sydney, New South Wales, Australia

  • Flinders Medical center

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.